PubMed Health⌕ Search

PubMed · 3922865

Low thyroidal T3 in nodular goitrous tissue.

Abstract

Six nodular tissues of non-treated and four of treated patients (suppressive treatment with thyroid hormones from three months to two years until the operation) with nodular non-toxic goitre contained low T3 (less than 1 ug/g w.w.). The results of iodothyronines and thyroglobulin (Tg) were compared with respective tissues containing T3 greater than 1 ug/g w.w. In non-treated patients, nodular tissues with low T3 and very high T4/T3 ratio showed T4 and Tg concentrations not different from the tissues with T3 greater than 1 ug/g w.w. In the goitres with low T3 of treated patients, T4 was also reduced but disproportionately to T3. Microscopically, nodular goitres with low T3 were characterized with gross fibrous infiltration and diffuse haemorrhage which was substantially different from histological findings in nodular goitres with T3 greater than 1 ug/g w.w. High T4/T3 ratio in the tissues with low T3 is similar to increased T4/T3 ratio in paranodular tissues of autonomously functioning adenomas. The results suggest that low T3 and high T4/T3 ratio in nodular goitrous tissue could be due to grossly impaired thyroid function or due to suppressed secretion of TSH.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Solter, D Tislarić, M Dominis, M Sekso. 1985. Low thyroidal T3 in nodular goitrous tissue.. https://doi.org/10.1055/s-2007-1013477

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[The use for recombinant human TSH in patients with toxic and non-toxic nodular goiter].

Radioiodine ((131)I) treatment for multinodular toxic and non-toxic goiter is therapeutic procedure especially used in patients with contraindication for surgery. (131)I treatment diminishes the size of the goiter and treats hyperthyroidism. Sometimes, due to low radio-iodine uptake (RAIU), this procedure should not be used. In patients with goiter, the elimination of medication or substances rich in iodine is the first step to increase RAIU. Recombinant TSH (rhTSH) enhances RAIU in metastases distant from thyroid cancer. Studies were performed in recent years using rhTSH to increase the radio-iodine uptake in multinodular toxic and non-toxic goiter. These methods led to enhanced radio-iodine uptake, decreased the level of activity of the (131)I administered, changed the distribution of (131)I in the thyroid, lowered the absorption dose, and increased the number of patients with hypothyroidism. The uses of rhTSH can lead to exacerbation of the signs and symptoms of hyperthyroidism, so patients should be hospitalized. Until now there has been no evidence that the adverse effects outweigh the positive results of using rhTSH. The use of rhTSH in benign goiter disease is not yet approved, but its positive activity in multinodular goiter is very interesting and promising.

Goiter, Nodular↗